BDSX Stock Overview
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Biodesix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.26 |
| 52 Week High | US$2.21 |
| 52 Week Low | US$1.03 |
| Beta | 1.12 |
| 1 Month Change | -13.10% |
| 3 Month Change | -36.04% |
| 1 Year Change | -27.59% |
| 3 Year Change | -92.07% |
| 5 Year Change | n/a |
| Change since IPO | -90.16% |
Recent News & Updates
Recent updates
With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
Mar 03
Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce
Jan 04It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
Jul 16A Second Look At Biodesix
Oct 18Biodesix expects Q3 revenue above the consensus
Oct 11Biodesix GAAP EPS of -$0.40 beats by $0.07, revenue of $10.95M beats by $2.12M
Aug 04Biodesix: Bad Diagnosis
May 26Analysts' Revenue Estimates For Biodesix, Inc. (NASDAQ:BDSX) Are Surging Higher
Mar 15Need To Know: Analysts Just Made A Substantial Cut To Their Biodesix, Inc. (NASDAQ:BDSX) Estimates
Nov 25Bearing In On Biodesix
Sep 13Time To Worry? Analysts Are Downgrading Their Biodesix, Inc. (NASDAQ:BDSX) Outlook
Aug 16Biodesix: Continued Concerns After The Boom-Bust Cycle
Jul 14Biodesix pops 6% on launch of SARS CoV-2 Neutralization Antibody Test
Jun 15Biodesix announces strategic partnership with Datavant
Jun 04Biodesix enrolls first patient in lung cancer study
May 26Shareholder Returns
| BDSX | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0.8% | 0.6% | 1.0% |
| 1Y | -27.6% | 2.2% | 21.9% |
Return vs Industry: BDSX underperformed the US Healthcare industry which returned 3.4% over the past year.
Return vs Market: BDSX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| BDSX volatility | |
|---|---|
| BDSX Average Weekly Movement | 8.1% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BDSX's share price has been volatile over the past 3 months.
Volatility Over Time: BDSX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 217 | Scott Hutton | www.biodesix.com |
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to establish the patient’s prognosis and help guide treatment decisions.
Biodesix, Inc. Fundamentals Summary
| BDSX fundamental statistics | |
|---|---|
| Market cap | US$143.17m |
| Earnings (TTM) | -US$52.15m |
| Revenue (TTM) | US$49.09m |
2.9x
P/S Ratio-2.7x
P/E RatioIs BDSX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BDSX income statement (TTM) | |
|---|---|
| Revenue | US$49.09m |
| Cost of Revenue | US$13.01m |
| Gross Profit | US$36.08m |
| Other Expenses | US$88.22m |
| Earnings | -US$52.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 73.50% |
| Net Profit Margin | -106.23% |
| Debt/Equity Ratio | 770.2% |
How did BDSX perform over the long term?
See historical performance and comparison